Researchers developed CheekAge, an epigenetic clock based on buccal cells, and found it predicted mortality risk with significant accuracy. This study validates CheekAge as a reliable aging biomarker, outperforming first-generation clocks.
Novo gets the green light for once-daily haemophilia drug following setbacks – Pharmaceutical Technology
Haemophilia is a rare condition that affects the blood’s ability to clot. Credit: Rembolle via Shutterstock. Novo Nordisk has secured approval from the US Food
December 24, 2024